Related Experiment Video
Updated: Feb 8, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
Published on: November 4, 2011
Anlotinib: First Global Approval
1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Abstract:
Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Laboratories are co-developing anlotinib (Focus V®) for the treatment of advanced cancer. Anlotinib is an oral small molecule inhibitor of multiple receptor tyrosine kinases, with a broad spectrum of inhibitory effects on tumour angiogenesis and growth. Anlotinib is approved in China for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have undergone progression or recurrence after ≥ 2 lines of systemic chemotherapy. Anlotinib is also undergoing phase II and/or III clinical development for various sarcomas and carcinomas in China, USA and Italy. This article summarizes the milestones in the development of anlotinib leading to this first approval for NSCLC.
Insights
Anlotinib, an oral tyrosine kinase inhibitor, is now approved in China for advanced non-small cell lung cancer (NSCLC) patients who progressed after chemotherapy. This marks a significant milestone for this targeted cancer therapy.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- Anlotinib is an oral small molecule inhibitor targeting multiple receptor tyrosine kinases.
- It exhibits broad-spectrum inhibition of tumor angiogenesis and growth.
- Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Laboratories are co-developing anlotinib.
Purpose of the Study:
- To summarize the development milestones of anlotinib.
- To highlight the drug's first approval for non-small cell lung cancer (NSCLC).
Main Methods:
- Review of anlotinib's development pathway.
- Summary of clinical development stages and regulatory approvals.
Main Results:
- Anlotinib is approved in China for advanced or metastatic NSCLC post-chemotherapy.
- Phase II and III clinical development is ongoing for various sarcomas and carcinomas in China, USA, and Italy.
Conclusions:
- Anlotinib's approval for NSCLC represents a key achievement in its development.
- The drug shows potential for treating various advanced cancers.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Global Climate Change
Introduction to Global Positioning System
Errors in Global Positioning System
Global Regulatory Systems
Field Application of Global Positioning System

